Zymeworks' $250M Royalty Deal: A New Blueprint for Biotech Funding

VANCOUVER, British Columbia and NEW YORK – March 02, 2026 – Zymeworks Inc. has secured a significant $250 million capital infusion from Royalty Pharma plc in a sophisticated financing deal that underscores the soaring value of its flagship cancer therapy, Ziihera® (zanidatamab-hrii). The agreement, structured as a non-recourse royalty-backed note, provides Zymeworks with immediate, non-dilutive funding, signaling a major vote of confidence in Ziihera's blockbuster potential and offering a compelling new model for biotech capital strategy.

Instead of issuing new stock, which would dilute the ownership of existing shareholders, Zymeworks will repay the note using 30% of the future worldwide royalties it receives from Ziihera sales. This arrangement allows the company to monetize a portion of its future revenue stream to fund present-day strategic priorities, including stock buybacks, potential acquisitions, and extending its operational cash runway well beyond 2028. The deal serves as both a validation of Zymeworks' proprietary science and a masterclass in modern financial engineering for the life sciences sector.

A Strategic Infusion Without Dilution

For biotechnology companies, capital is the lifeblood that fuels long and expensive development cycles. This deal provides Zymeworks with substantial financial firepower without the common trade-off of shareholder dilution. The $250 million injection significantly strengthens a balance sheet that already held a respectable cash position, extending the company’s projected cash runway from mid-2027 to beyond 2028. This extended runway gives the company crucial breathing room to advance its earlier-stage pipeline and execute its long-term vision.

“This strategic funding provides non-dilutive capital that enhances our flexibility to continue repurchasing shares at current prices, which we believe represents a compelling discount to our estimate of intrinsic value,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. He added that the capital provides “additional capacity to pursue strategic acquisitions that meet our rigorous risk-adjusted return criteria and fund our cash runway beyond 2028.”

This move comes as Zymeworks has successfully managed its expenditures, with operating expenses declining by 7% in 2025 and a further 20% reduction in adjusted gross operating expenses projected for 2026. By securing this funding, Zymeworks can now aggressively pursue its capital allocation strategy. This includes deploying its previously authorized $125 million share repurchase program and hunting for strategic assets that align with its “5 by 5” strategy to build a diverse pipeline of antibody-drug conjugates (ADCs) and multispecific antibody therapeutics.

The $250 Million Bet on Ziihera

The foundation of this entire transaction is the immense promise of Ziihera, a bispecific HER2-directed antibody developed using Zymeworks' proprietary Azymetric™ platform. The drug is already on the market in the U.S. with an accelerated FDA approval for treating previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC), an aggressive cancer with limited options.

However, the real excitement, and likely the core of Royalty Pharma’s investment thesis, lies in Ziihera’s potential in much larger indications, particularly HER2-positive gastroesophageal adenocarcinoma (GEA). Recent clinical data from the HERIZON-GEA-01 trial has been exceptionally strong, fueling a dramatic surge in optimism. Analyst consensus for Ziihera’s peak annual sales has nearly doubled in the past year, rocketing from approximately $1.2 billion to over $2.3 billion. This reflects a growing conviction that Ziihera can effectively compete with, and potentially outperform, established therapies in the crowded HER2-positive cancer space.

Royalty Pharma, the industry’s largest buyer of biopharmaceutical royalties, is known for its meticulous due diligence and focus on high-quality assets. Their investment is a powerful external validation of Ziihera’s clinical and commercial prospects.

“The recent clinical results from HERIZON-GEA-01 for Ziihera in first-line metastatic gastroesophageal adenocarcinoma (mGEA) underscore its potential to prolong survival in a disease with poor prognosis and urgent need of new treatment options,” noted Pablo Legorreta, Chief Executive Officer of Royalty Pharma. “This transaction enables us to participate in the long-term value of this important therapy while providing Zymeworks capital to achieve their strategic and financial goals.”

Deconstructing the Deal's Mechanics

The structure of the royalty-backed note is designed to align the interests of both parties. Zymeworks receives the full $250 million upfront. In return, Royalty Pharma will receive 30% of the tiered royalties Zymeworks earns from its global partners, Jazz Pharmaceuticals and BeOne Medicines, who are commercializing Ziihera. This leaves Zymeworks with 70% of the royalty stream during the repayment period, preserving a significant portion of its near-term cash flow from the drug's sales.

Crucially, the deal includes clear repayment caps. Royalty Pharma’s return is capped at 1.65 times the initial $250 million if repaid by the end of 2033, or 1.925 times the amount thereafter. Once the cap is reached, the full royalty stream reverts to Zymeworks. This structure protects Zymeworks from uncapped payments and gives it a clear path to regaining 100% of its Ziihera royalty income in the long term. The note is also non-recourse, meaning Royalty Pharma’s repayment is solely dependent on Ziihera’s success; Zymeworks' other corporate assets are not at risk.

Furthermore, Zymeworks retains the full value of all potential future milestone payments from its partners. These are substantial, with up to $1.5 billion in potential regulatory and commercial milestones still on the table. This ensures that while Zymeworks has monetized a slice of its future royalties, it has kept the significant upside from Ziihera's continued clinical and commercial achievements entirely for itself.

Reshaping the Biotech Capital Landscape

The Zymeworks-Royalty Pharma transaction is more than just a win for one company; it is a prominent example of a broader evolution in biotech financing. For decades, emerging biotechs relied heavily on venture capital and dilutive public offerings. Royalty-backed financing offers a mature alternative for companies that have successfully advanced an asset to late-stage development or commercialization.

This model allows a company to leverage a de-risked asset to fund its next wave of innovation without ceding equity. It provides a source of non-dilutive growth capital that can be used with greater flexibility than typical venture rounds, funding everything from R&D and commercial launches to share buybacks and acquisitions. As the biopharmaceutical industry continues to mature, and as capital markets fluctuate, such innovative financing structures are becoming an increasingly vital tool. The deal provides Zymeworks with the capital to transform into a self-sustaining, royalty-driven biopharmaceutical entity, setting a powerful precedent for its peers across the industry.